title: High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.
abstract: BACKGROUND
  The mesenchymal-epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted therapy of TNBC using MET inhibitors.
  
  
  METHODS
  We determined expression of MET in formalin-fixed paraffin-embedded surgical specimens of TNBC by immunohistochemistry. Recurrence-free and overall survival was analysed with Cox models adjusted for clinical and pathological factors.
  
  
  RESULTS
  Immunostaining for MET was classified as high in 89 of 170 (52%) tumours. MET expression was more frequently observed in G3 carcinomas (P=0.02) but was not significantly associated to any of the other clinical or pathological parameters. High MET expression predicted shorter survival of the patients. Multivariate Cox proportional hazards regression analyses identified MET to be an independent prognostic factor for recurrence (adjusted hazard ratio (HR) for recurrence 3.43; 95% confidence interval (CI) 1.65-7.12; P=0.001) and death (adjusted HR for death 3.74; 95% CI 1.65-8.46; P=0.002).
  
  
  CONCLUSIONS
  These results provide further evidence that the MET pathway could be exploited as a target for TNBC.
authors: Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
authors: F
authors: F
authors: Zagouri
authors: Z
authors: Z
authors: Bago-Horvath
authors: F
authors: F
authors: Rössler
authors: A
authors: A
authors: Brandstetter
authors: R
authors: R
authors: Bartsch
authors: C A
authors: CA
authors: Papadimitriou
authors: C
authors: C
authors: Dimitrakakis
authors: A
authors: A
authors: Tsigginou
authors: I
authors: I
authors: Papaspyrou
authors: A
authors: A
authors: Giannos
authors: M-A
authors: MA
authors: Dimopoulos
authors: M
authors: M
authors: Filipits
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012008:Recurrence; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone